TiumBio Co., Ltd. (KOSDAQ:321550)

Market Cap	86.15B
Revenue (ttm)	6.79B
Net Income (ttm)	-20.64B
Shares Out	26.71M
EPS (ttm)	-799.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,734
Average Volume	76,797
Open	3,265.00
Previous Close	3,265.00
Day's Range	3,040.00 - 3,265.00
52-Week Range	2,900.00 - 8,980.00
Beta	0.70
RSI	46.28
Earnings Date	Mar 21, 2025

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. TiumBio Co., Ltd. was founded in 2016 and is based in Seongnam-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 42
• Stock Exchange: KOSDAQ
• Ticker Symbol: 321550

Financial Performance

In 2024, TiumBio's revenue was 6.79 billion, an increase of 38.65% compared to the previous year's 4.90 billion. Losses were -20.64 billion, 15.3% more than in 2023.